NMS · Biotechnology

UPB (UPB) Stock

$7.25 +5.53% NMS: UPB Healthcare

Valuation

MetricValue
Price$7.25
Market Cap$394.54M
P/E Ratio-3.02
P/B Ratio1.29
P/S Ratio135.29
EPS (TTM)$-2.66
52-Week High$33.68
52-Week Low$5.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-42.06%
ROA-40.40%
ROCE-47.06%
Gross Margin-5333.33%
Operating Margin-5333.33%
Net Margin-47.19%
Debt/Equity0.00
Current Ratio27.08

Annual Financials (USD)

Metric2022202320242025
Revenue$1.0M$2.0M$2.0M$3.0M
Operating Profit$-24.0M$-40.0M$-78.0M$-160.0M
Net Profit$-24.0M$-21.0M$-63.0M$-143.0M
EPS$-0.66$-1.05$-1.49$-2.66
Op Margin-1972.7%-1685.5%-3281.2%-5618.8%

Balance Sheet (USD)

Metric2022202320242025
Total Assets$18.0M$117.0M$482.0M$354.0M
Total Liabilities$125.0M$240.0M$12.0M$14.0M
Cash$17.0M$26.0M$326.0M$102.0M
Borrowings$0$0$2.0M$1.0M

Latest News

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? Zacks · Jul 14, 2026 Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage? Insider Monkey · Jun 25, 2026 Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026? Insider Monkey · Jun 23, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 GlobeNewswire · Jun 14, 2026 JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35 MT Newswires · Jun 12, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-19.0M$-38.0M$-59.0M$-133.0M
Investing Cash Flow$0$-83.0M$-60.0M$-94.0M
Financing Cash Flow$0$0$-4.0M$0
Net Cash Flow$-9.0M$9.0M$300.0M$-224.0M
Free Cash Flow$-19.0M$-38.0M$-60.0M$-133.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-31.15%
Quick Ratio23.14
Interest Coverage—
Return 1Y-44.49%
Return 3Y—
Return 5Y—

Ownership

Insiders Held14.88%
Institutions Held88.43%
Institutions Float Held103.88%
Institutional HolderSharesReport Date
FMR, LLC8,101,5632026-03-31
Orbimed Advisors LLC.5,693,5892026-03-31
Blackrock Inc.3,370,6892026-03-31
Decheng Capital LLC2,724,8682026-03-31
Enavate Sciences Gp, LLC 2,459,7032026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMLX $22.82 -5.66% -8.69 $2.54B 0.00%
NTLA $10.89 +2.06% -3.55 $1.22B 0.00%
NVAXNovavax, Inc. $7.61 +2.01% -13.81 $1.25B 0.00%
PHVS $32.62 -3.05% -9.75 $2.28B 0.00%
RLAY $18.37 +0.44% -7.52 $3.22B 0.00%

About UPB

UPB is led by CEO E. Rand Sutherland, employs 52 people, headquartered in US, publicly traded since 2024.

UPB stock trades at $7.25 with a market capitalization of $394.54M. The stock is valued at a price-to-earnings (P/E) ratio of -3.02, price-to-book of 1.29, price-to-sales of 135.29. Over the past 52 weeks the stock has ranged between $5.85 and $33.68, and currently trades 78.5% below its 52-week high.

On profitability, UPB generates a return on equity (ROE) of -42.06%, return on capital employed of -47.06%, an operating margin of -5333.33%, a net profit margin of -47.19%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides